Introduction {#section1-2324709620947891}
============

Drug-induced thrombocytopenia is a differential diagnosis for consideration when acute thrombocytopenia is encountered in the outpatient or inpatient setting. Percutaneous coronary intervention is a common procedure, following which patients require antiplatelet therapy to prevent acute thrombosis at the site of stent placement or balloon angioplasty. The mechanism of thrombocytopenia induced by different antiplatelet therapies varies. The timing of the onset of thrombocytopenia since the procedure and the antiplatelet therapy's underlying pathophysiologic mechanism, management, and resolution of thrombocytopenia are key data points that help implicate the drug responsible for the clinical manifestation of thrombocytopenia.

Drug-induced thrombocytopenia may occur due to antibody formation following the exposure to a drug, and this generally takes 5 to 7 days. Naturally occurring preexisting antibodies may produce rapid-onset thrombocytopenia when a drug molecule binds to a platelet receptor inducing a conformational change thus rendering it to be an antigen target for naturally occurring antibodies. Such platelets are cleared from the circulation rapidly, resulting in marked thrombocytopenia in certain cases that could be potentially life threatening.^[@bibr1-2324709620947891]^

Case {#section2-2324709620947891}
====

A 66-year-old female with history of hypertension presented with non-ST elevation myocardial infarction, had drug eluting stent placed in first obtuse marginal artery of left circumflex coronary artery. Started on antiplatelet medications aspirin 81 mg, ticagrelor 90 mg (which was later transitioned to clopidogrel 75 mg), as well as tirofiban 12.5 mg (for 12 hours only). Platelet count was 195 000 along with hemoglobin 12.0 and white blood cells 7.6 of the morning of procedure, dropped to 15 000 platelet count, 11.6 hemoglobin and 12.6 white blood cell count the next morning. On physical examination, multiple petechiae on all extremities, bruising, and active bleeding at intravenous sites on arms were noted. At this time, differential diagnoses included disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, immune thrombocytopenia, or heparin-induced thrombocytopenia. Due to active bleeding resulting in blood loss anemia, 2 units of platelets were transfused, following transfusion, patient was observed, and platelet count remained adequate and even increased the following day. Platelet count was 141 000, with hemoglobin of 10.6 and white blood cell count of 11.4 that night. The next morning, platelet count dropped to 89 000 with hemoglobin of 10.5 and white blood cell count of 7.9, but no more platelets were transfused, and platelet count 133 000 that afternoon, final platelet count was 142 000 with hemoglobin of 10.7 and white blood cell count of 8.6 next morning after which the patient was discharged on clopidogrel and aspirin ([Figure 1](#fig1-2324709620947891){ref-type="fig"} and [Table 1](#table1-2324709620947891){ref-type="table"}). Peripheral blood smear and laboratory findings during nadir of thrombocytopenia showed thrombocytopenia with large platelets, no platelet clumps or satellitosis, normal red blood cell morphology, no immature blasts, haptoglobin normal 67 mg/dL, D-dimer elevated to 0.64 µg/mL FEU, and lactate dehydrogenase to elevated 1257 U/L ([Table 2](#table2-2324709620947891){ref-type="table"}). Patient followed-up with hematologist 1 week after discharge.

![Platelet count over course of admission.](10.1177_2324709620947891-fig1){#fig1-2324709620947891}

###### 

Platelet and Blood Counts Throughout Admission.

![](10.1177_2324709620947891-table1)

  Time                      Platelet count (K/µL)   White blood cells (K/µL)   Hemoglobin (g/dL)   Hematocrit (%)
  ------------------------- ----------------------- -------------------------- ------------------- ----------------
  October 9, 2019; 21:25    221                     8.6                        12.8                40.0
  October 10, 2019; 3:55    195                     7.6                        12.0                37.4
  October 11, 2019; 10:07   15                      12.6                       11.6                35.9
  October 11, 2019; 11:30   16                      12.7                       11.3                35.1
  October 11, 2019; 17:18   141                     11.4                       10.6                33.4
  October 12, 2019; 6:40    89                      7.9                        10.5                33.9
  October 12, 2019; 15:17   133                                                                    
  October 13, 2019; 5:21    142                     8.6                        10.7                33.5

###### 

Laboratory Results to Rule Out Other Etiologies of Thrombocytopenia.

![](10.1177_2324709620947891-table2)

  Time                      Lactate dehydrogenase, normal (313-618 U/L)                 D-dimer, normal (0.00-0.48 µg/mL FEU)                 Haptoglobin, normal (43-212 mg/dL)   Peripheral blood smear
  ------------------------- ----------------------------------------------------------- ----------------------------------------------------- ------------------------------------ -------------------------------------------------------------------------------------
  October 11, 2019; 11:30   1257                                                        0.64                                                  67                                   Thrombocytopenia with large platelets, negative for platelet clumps or satellitosis
  October 12, 2019; 6:40    Heparin-induced platelet antibodies: 0.188 (normal \<0.3)   Heparin-induced platelet antibodies ELISA: negative                                        

Abbreviation: ELISA, enzyme-linked immunosorbent assay.

Discussion {#section3-2324709620947891}
==========

The most likely agent to have induced the aforementioned case is tirofiban; there are documented cases of tirofiban drug--induced thrombocytopenia with proposed mechanism due to drug-dependent antibody formation ([Table 3](#table3-2324709620947891){ref-type="table"}). Tirofiban is a GP IIb/IIIa antagonist; other drugs in this class have been documented to induce thrombocytopenia as well, but rates for tirofiban appears to be the highest, and the reason is unclear. These antibodies are thought to be either naturally occurring or induced from conformational changes to GP IIb/IIIa binding site after binding to the GP IIb/IIIa receptor; binding of these drugs to the receptor precipitates an epitope much more specific for platelet surface antigens. If there are no preformed antibodies, but epitopes induce antibody formation, thrombocytopenia onset is usually within 5 to 7 days of starting tirofiban, and thrombocytopenia is generally less severe. If antibodies are naturally occurring, which we believe to be the case for our patient, thrombocytopenia is rapid (onset within \<24 hours) and severe, but also resolves quickly (usually within a day) after cessation of inducing drug. This rapid fall and rise of platelets is due to preformed antibodies binding platelets in presence of tirofiban, but when drug is stopped and cleared from circulation, bound platelets are cleared via antibody-mediated consumption by reticulocyte endothelial system, and new unbound platelets do not have epitopes that are recognized by antibodies, and thus the thrombocytopenia abates.^[@bibr2-2324709620947891]^

###### 

Previous Cases of Tirofiban Drug--Induced Thrombocytopenia.

![](10.1177_2324709620947891-table3)

  Age and sex of patient in cases^[a](#table-fn2-2324709620947891){ref-type="table-fn"}^   Initial platelet count   Post-tirofiban platelet count   Time (hours)^[b](#table-fn3-2324709620947891){ref-type="table-fn"}^
  ---------------------------------------------------------------------------------------- ------------------------ ------------------------------- ---------------------------------------------------------------------
  50 years/Male^[@bibr3-2324709620947891]^                                                 246                      \<1                             24
  44 years/Male^[@bibr4-2324709620947891]^                                                 411                      7                               18
  69 years/Female^[@bibr5-2324709620947891]^                                               224                      2                               \<24
  79 years/Male^[@bibr6-2324709620947891]^                                                 233                      6                               23
  68 years/Male^[@bibr7-2324709620947891]^                                                 234                      3                               8
  58 years/Male^[@bibr8-2324709620947891]^                                                 403                      7                               7
  50 years/Male^[@bibr9-2324709620947891]^                                                 265                      5                               4

Represents patients in previous documented cases of tirofiban drug--induced thrombocytopenia.

Represents time in hours for tirofiban drug--induced thrombocytopenia to manifest.

Conclusion {#section4-2324709620947891}
==========

Tirofiban and clopidogrel/ticagrelor can cause thrombocytopenia, but onset in this case is unusual: acute antibody reaction would be expected within hours, not delayed 30 hours after starting antiplatelet medication, and nonacute reaction would present 1 to 2 weeks out. Other etiologies on differential were not supported by peripheral blood smear or laboratory findings, such as thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, and heparin-induced thrombocytopenia ([Table 2](#table2-2324709620947891){ref-type="table"}). Thus, we believe this case to be an abnormal presentation of drug-induced immune thrombocytopenia. It is important to keep this adverse reaction of antiplatelet class drugs in mind especially when newly started for a patient, and to appropriately monitor and manage when thrombocytopenia does occur with transfusion or drug cessation.
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